HPV signatures may predict anal cancer risk a decade later

NCT ID NCT06522256

Recruiting now Knowledge-focused Sponsor: ANRS, Emerging Infectious Diseases Source: ClinicalTrials.gov ↗

First seen Jan 07, 2026 · Last updated May 14, 2026 · Updated 17 times

Summary

This study follows up with 100 people who were part of the ANRS IPERGAY trial to see if certain HPV molecular signatures are linked to high-grade anal lesions or cancer 10 years later. Researchers will use high-resolution anoscopy to check for abnormalities. The goal is to better understand long-term risks, not to test a new treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Hôpital Saint-Louis - SMIT
RECRUITING

Paris, 75010, France

Contact Email: •••••@•••••

Contact
Hôpital Tenon - SMIT
RECRUITING

Paris, 75020, France

Contact

Contact Email: •••••@•••••
Hôpital de la Croix Rousse - SMIT
RECRUITING

Lyon, 69004, France

Contact

Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

ANAL CANCER HPV INFECTION